Used as a potent inhibitor of poly (ADP-ribose) polymerase (PARP), particularly PARP-1 and PARP-2, rucaparib camsylate is applied in the treatment of certain cancers, especially ovarian and breast cancers associated with BRCA1 or BRP2 gene mutations. It works by blocking DNA repair mechanisms in cancer cells, leading to cell death through synthetic lethality. The compound is utilized in patients with recurrent or advanced disease who have received prior chemotherapy. Its application allows for targeted therapy with improved efficacy in genetically defined patient populations.